Cara Therapeuticsreports summary results from its Phase 1 safety and pharmacokinetic trial of Oral CR845 in chronic kidney disease patients undergoing hemodialysis.

“We are pleased to establish that plasma levels of CR845 attained with oral tablets equaled or exceeded plasma levels previously associated with clinically efficacious I.V. CR845 doses in hemodialysis patients with moderate-to-severe CKD-associated pruritus,” said Frédérique Menzaghi, Ph.D., Vice President of Research and Development at Cara Therapeutics.